Discovery of Orally Bioavailable Cathepsin S Inhibitors for the Reversal of Neuropathic Pain
Journal of Medicinal Chemistry2008Vol. 51(18), pp. 5502–5505
Citations Over TimeTop 10% of 2008 papers
Osamu Irie, Takatoshi Kosaka, Takeru Ehara, Fumiaki Yokokawa, Takanori Kanazawa, Hajime Hirao, Astuko Iwasaki, Junichi Sakaki, Naoki Teno, Yuko Hitomi, Genji Iwasaki, Hiroaki Fukaya, K. Nonomura, Keiko Tanabe, Shinichi Koizumi, Noriko Uchiyama, Stuart Bevan, Marzia Malcangio, Clive Gentry, Alyson J. Fox, Mohammed Yaqoob, Andrew J. Culshaw, Allan Hallett
Abstract
Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration.
Related Papers
- → Cysteine Protease Cathepsins in Atherosclerosis-Based Vascular Disease and Its Complications(2011)136 cited
- → Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases(2017)108 cited
- → Cystatin C and cathepsins in cardiovascular disease(2008)32 cited
- → Therapeutic potential of targeting cathepsin S in pulmonary fibrosis(2021)30 cited
- → Role of elastolytic cathepsins in vascular remodeling(2004)1 cited